Assessing the Landscape for Prescription Drug Regulation, Promotion, and Advocacy
In a recent post on the IVI-sponsored Health Affairs featured blog series, Jerry Avorn sums up the status quo in medical regulation and evidence-based prescribing. Avorn uses his commentary to call out flaws in the 21st Century Cures Act, illustrate how the appointment of a new FDA Commissioner may influence “right-to-try” laws, and discuss the promise […]
Proposed Options to Modernize and Strengthen Drug Pricing Regulations
In a recent post on the IVI-sponsored Health Affairs featured blog series, Tim Horn and Sean Dickson propose changes to the current system of drug pricing regulation focusing on four areas: Pricing formulas Price increase penalties Pool pricing guidelines Reporting transparency Read the full article here. About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation […]
Lessons Learned from Genentech-Priority Health Pilot in Illustrating Outcomes-Based Contracting Challenges
In a recent post on the IVI-sponsored Health Affairs featured blog series, John Fox and Marc Waltrous provide a detailed analysis of the Genentech-Priority Health Pilot program, outlining the background, key considerations, pilot design, and take-aways to illustrate the challenges of a successful outcomes-based contracting agreement. Read the full article here. About the Health Affairs/IVI Featured Blog […]
Addressing Outcomes-Based Pricing Agreements
In a recent post on the IVI-sponsored Health Affairs featured blog series, Daniel Blumenthal, Mark Linthicum (IVI Director of Scientific Communications), and Sachin Kamal-Bahl (Member, IVI Strategic Advisory Panel) discuss challenges in establishing outcomes-based pricing agreements for pharmaceuticals and potential strategies for overcoming obstacles. Strategies discussed include focusing on legal and regulatory changes, increased information sharing, […]
Patent Buyouts and Licensing Changes as a Strategy for Lowering Brand Drug Prices
In a recent post on the IVI-sponsored Health Affairs featured blog series, Jonathan Silver suggests the key to lowering brand drug prices may be found through patent buyouts and changes to licensing policy. In particular, Silver proposes that non-profit entities be created and funded to purchase and license intellectual property rights for certain branded drugs. Read […]
Rachel Sachs Summarizes Scott Gottlieb’s FDA Commissioner Confirmation Hearing
In a recent post on the IVI-sponsored Health Affairs featured blog series, Rachel Sachs summarizes Scott Gottlieb’s FDA Commissioner confirmation hearing and top-lines four areas of questioning: the drug approval process, the character of the FDA, the opioid epidemic, and soaring drug prices. Also notable for not being mentioned, Rachel is curious how Dr. Gottlieb will address the FDA’s relationship with […]
Unique Challenges of Assessing the Value of Treatments for Rare Diseases
In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI’s Executive Director, Darius Lakdawalla, and Anupam Jena recommend that creators of value frameworks recognize the unique issues associated with valuing treatments for rare diseases by adopting societal, as well payer-oriented perspectives. Included in this assessment are the important roles of treatment spillovers, societal preferences about health […]
Balancing the Use of Cost-Effectiveness Analysis in Healthcare Innovations
In a recent post on the IVI-sponsored Health Affairs featured blog series, Peter Neumann and James Baumgardner addresses cost effectiveness analysis as applied across different types of of healthcare interventions, and the disproportionate emphasis placed on pharmaceuticals relative to overall healthcare spending. Neumann and Baumgardner outline some reasons why surgical CEAs are more challenging that drug CEAs, […]
A Win-Win Strategy for Improving Access to Hepatitis C Medicines
In a recent post on the IVI-sponsored Health Affairs blog series, Neeraj Sood, Gillian Buckley, and Brian Strom present a novel “win-win” scenario for improving patient access to Hepatitis C medicines. By arranging for pharmaceutical patent holders to license their patents to the federal government, the agreement could potentially provide curative treatment to nearly a half […]
Bateman-House, McBride-Folkers and Caplan Examine “Right to Try” Bill
In a recent post on the IVI-sponsored Health Affairs featured blog series, Alison Bateman-House, Kelly McBride-Folkers and Arthur Caplan discuss the Trickett Wendler Right to Try Act of 2017. The authors outline key obstacles likely to limit the effectiveness of the law and present some alternative measures for achieving access to experimental drugs for patients. Read […]